suzhou connect biopharmaceuticals, ltd. is a pharmaceuticals company based out of 10th floor, xiangtang development building, #3 chaoyang dong rd, taicang, china.
Company profile
Ticker
CNTB
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CNTB stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
16 Apr 24
6-K
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
16 Apr 24
6-K
Current report (foreign)
12 Feb 24
6-K
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
12 Dec 23
6-K
Exclusive License and Collaboration Agreement
21 Nov 23
6-K
Current report (foreign)
1 Nov 23
6-K
Current report (foreign)
20 Oct 23
6-K
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
12 Sep 23
6-K
Current report (foreign)
12 Sep 23
UPLOAD
Letter from SEC
10 Aug 23
Transcripts
Latest ownership filings
SC 13D/A
Panacea Innovation Ltd
27 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
27 Feb 24
SC 13D
Panacea Innovation Ltd
13 Feb 24
SC 13G/A
BioFortune Inc
13 Feb 24
SC 13G/A
Wei Zheng
13 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
20 Dec 23
144
Notice of proposed sale of securities
18 Dec 23
144
Notice of proposed sale of securities
18 Dec 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
14 Dec 23
144
Notice of proposed sale of securities
12 Dec 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2023
64.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 8.19 bn |
Total shares | 35.25 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 6.99 mm | $5.73 bn |
BioFortune | 5.89 mm | $0.00 |
Shanghai Minhui Enterprise Management Consulting Partnership | 5.31 mm | $0.00 |
Advantech Capital II | 4.76 mm | $24.53 mm |
Qiming Venture Partners V | 3.20 mm | $0.00 |
Qiming Venture Partners VII | 3.20 mm | $16.47 mm |
Huang James | 2.82 mm | $2.16 mm |
BLK Blackrock | 1.13 mm | $921.59 mm |
Adage Capital Partners GP, L.L.C. | 650.00 k | $532.35 mm |
Ubs Oconnor | 603.90 k | $468.63 mm |
News
HC Wainwright & Co. Maintains Buy on Connect Biopharma Hldgs, Raises Price Target to $8
17 Apr 24
Connect Biopharma Hldgs FY EPS $(1.08) Up From $(2.15) YoY
16 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
3 Apr 24
HC Wainwright & Co. Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $7
4 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
2 Feb 24